CEL-SCI

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Update on Phase 3 Cancer Trial Results.

CEL-SCI Announces Update on Phase 3 Cancer Trial Results

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies.

CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at H.C.

CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports third quarter fiscal 2020 financial results.

CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment.

CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment

CEL-SCI: What's Next

Cel-Sci: A Zombie Biotech Company

CEL-SCI's Multikine: Can It Really Be This Good?

Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?

Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment

Cel-Sci: It's All Happening

CEL-SCI announced that it is developing an immunotherapy for COVID-19 based on its LEAPS peptide technology.

Cel-Sci: LEAPS And COVID-19

CEL-SCI: LEAPS & COVID-19

Cel-Sci: The Upside Is Still There

Cel-Sci: Little Known Drug Validates Multikine's Investigation Goals

CEL-SCI: Food For Thought Before The Big Day

CEL-SCI: The Homestretch

The mechanism of action for cytokines in helping the immune system respond to malignant growth in the head and neck has been well documented by medical research.

Bearish CEL-SCI Article Ignored Scientific Evidence And Misinterpreted Multikine's Clinical Trial Design

Multikine's Phase 3 trial accounts for the short half-lives of cytokines post administration, which may lead to significant improvements in its clinical profile compared to Phase 2.

CVM: Multikine's Phase 2 Trial Design May Have Grossly Understated Its Efficacy

The world's largest head and neck cancer study should have ended in late 2018 but patients appear to be living longer.

CEL-SCI's Multikine: The Gold Standard Endpoint Should Prevent Trial Bias

The world's largest head and neck cancer study should have ended in late 2018, but patients appear to be living longer.

CEL-SCI's Multikine Trial: Learning From Bristol-Myers' Ipilimumab

Multikine is a cytokine-based immunotherapeutic compound intended to cure Head and Neck Squamous-Cell Carcinoma, which is currently being tested in a large Phase III trial.

CEL-SCI: On The Verge Of Approval

G1 Therapeutics

Pfizer

These stocks were huge winners last week. But can their momentum continue?

These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

May 8, 2019 Cel-Sci Corporation released a letter to investors indicating the Phase 3 Multikine trial had not yet reached its endpoint of 298 endpoints (deaths) in the two arms.

Cel-Sci's Phase 3 Multikine Trial Has 'Not Yet Hit The Primary Endpoint'

CEL-SCI's Multikine Phase III Trial in Squamous Cell Cancer of Head and Neck Continues as the End-Point Has Still Not Yet Been Reached.

CEL-SCI'S Phase III Trial In Head & Neck Cancer My Analysis

News for CEL-SCI Stock (CVM)